Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis

被引：0
|
作者：
Duparc, Helene
Muller, Delphine
Antony-Debre, Ileana
Marty, Caroline
Debili, Najet
Villeval, Jean-Luc
Plo, Isabelle
Vainchenker, William
Gilles, Laure
Raslova, Hana
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141092
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
    Pandey, Kamal
    Park, Nahee
    Park, Kyung-Soon
    Hur, Jin
    Cho, Yong Bin
    Kang, Minsil
    An, Hee-Jung
    Kim, Sewha
    Hwang, Sohyun
    Moon, Yong Wha
    CANCERS, 2020, 12 (12) : 1 - 17
  • [42] PHARMACEUTICAL INHIBITION OF CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) IN GLIOBLASTOMA
    Nuga, Oluwademilade
    Meng, Yuling
    Berezovsky, Artem
    Nelson, Kevin
    deCarvalho, Ana
    NEURO-ONCOLOGY, 2020, 22 : 94 - 95
  • [43] Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation
    Bockstaele, Laurence
    Bisteau, Xavier
    Paternot, Sabine
    Roger, Pierre P.
    MOLECULAR AND CELLULAR BIOLOGY, 2009, 29 (15) : 4188 - 4200
  • [44] Inducible deletion of CDK4 and CDK6-deciphering CDK4/6 inhibitor effects in the hematopoietic system
    Maurer, Barbara
    Brandstoetter, Tania
    Kollmann, Sebastian
    Sexl, Veronika
    Prchal-Murphy, Michaela
    HAEMATOLOGICA, 2021, 106 (10) : 2624 - 2632
  • [45] Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment
    Liu, Minghui
    Liu, Hongyu
    Chen, Jun
    ONCOLOGY REPORTS, 2018, 39 (03) : 901 - 911
  • [46] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Kashiwagi, Shinichiro
    Asano, Yuka
    Goto, Wataru
    Takada, Koji
    Takashima, Tsutomu
    Morisaki, Tamami
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [47] P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
    Li, Paiyun
    Zhang, Xuehong
    Gu, Liankun
    Zhou, Jing
    Deng, Dajun
    PLOS ONE, 2019, 14 (10):
  • [48] Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
    Daniele Cretella
    Claudia Fumarola
    Mara Bonelli
    Roberta Alfieri
    Silvia La Monica
    Graziana Digiacomo
    Andrea Cavazzoni
    Maricla Galetti
    Daniele Generali
    Pier Giorgio Petronini
    Scientific Reports, 9
  • [49] The novel potential of palbociclib (CDK4/6 inhibitor) in the treatment of triple-negative breast cancer
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takahashi, Katsuyuki
    Takashima, Tsutomu
    Noda, Satoru
    Onoda, Naoyoshi
    Tomita, Shuhei
    Hirakawa, Kosei
    Ohira, Masaichi
    CANCER RESEARCH, 2017, 77
  • [50] Effect of CDK4/6 Inhibitor Palbociclib and Metformin in Ovarian Cancer: Cyclin D as a new Target?
    Tsibulak, I
    Hagenbuchner, J.
    Ausserlechner, M.
    Wieser, V
    Marth, C.
    Zeimet, A. G.
    Fiegl, H.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (04) : 436 - 436
12345